Study analysis · Journal of hepatology · 2023
46 out of 1,000 people develop fatty liver disease each year – and it's not from alcohol.
Every year, about 46 out of every 1,000 adults get non-alcoholic fatty liver disease (NAFLD), a buildup of fat in the liver not caused by alcohol.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study looked at many other studies to figure out how many people get a liver disease called NAFLD each year. It found that some groups, like men and people who are overweight, are more likely to get it. But this doesn't prove that being male or overweight causes the disease – it just shows they are connected.
What’s the bottom line?
Scientists combined 63 studies with over 1.2 million people to find out how many new cases of fatty liver disease occur each year. They found that about 46 out of 1,000 people develop it each year.
How strong is this study?
This study is high quality because it combined results from over a million people, which makes the numbers more trustworthy. The researchers carefully chose good studies to include. However, we only have the summary (abstract) of the study, so we can't check all the details ourselves. That means we should be a little careful about trusting everything completely.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
0 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 539 / 100
Probability of being correct
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
This design cannot establish causation — the findings describe an association, not a cause. This is a systematic review of cohort studies, which are observational. Cohort studies can show associations but cannot prove causation due to potential confounding factors.
No Conflicts
No conflicts of interest identified
No conflicts of interest identified; no funding or disclosure information provided in the text.
The text does not include any conflict of interest, funding, or author affiliation details. The study appears to be an independent meta-analysis, but without full disclosure, the absence of reported conflicts cannot be confirmed.
Key takeaways
- 01
Each year, about 46 out of 1,000 people get fatty liver disease.
- 02
Men get it more often than women.
- 03
Overweight people get it about 3 times more than normal-weight people.
- 04
Smokers get it more often.
- 05
This is a high number, meaning fatty liver disease is a common and growing health problem worldwide.
Surprising findings
- Smokers had a 71% higher NAFLD incidence than non-smokers.Most people associate smoking with lung cancer and heart disease, not fatty liver. This finding highlights an underappreciated link.
- The incidence of NAFLD increased after 2010, independent of study location and setting.One might expect the increase to be due to rising obesity rates, but the trend persisted even after adjusting for these factors, suggesting other drivers.
Practical takeaways
Maintain a healthy weight – especially if you're male or overweight – to significantly lower your risk of developing NAFLD.
This is based on observational data; full paper not available to verify methodology. Study has published corrections.
low confidenceIf you smoke, quitting may reduce your risk of fatty liver disease in addition to other health benefits.
Causal link not established; based on association from meta-analysis. Full text not available.
low confidenceMonitor liver health through regular check-ups, especially if you belong to a high-risk group (male, overweight, smoker).
Abstract does not specify screening recommendations; extrapolation from incidence data.
low confidenceWhy this study matters
Global NAFLD Incidence: 4,613 per 100,000
A meta-analysis of 63 studies with over 1.2 million adults found that the global incidence of NAFLD is 4,612.8 new cases per 100,000 person-years. This means roughly 4.6% of adults develop NAFLD each year.
This is a huge number – millions of new cases annually – highlighting a growing global health crisis that often goes unnoticed.
Men vs. Women: A Stark Difference
Men had a significantly higher incidence (5,943.8 per 100,000) compared to women (3,671.7 per 100,000), a difference of about 62%.
Many people assume liver disease is mostly from alcohol, but this shows non-alcoholic fatty liver hits men harder, possibly due to hormonal or metabolic differences.
Obesity Triples Your Risk
Overweight/obese individuals had about a threefold higher incidence (8,416.6 per 100,000) compared to normal-weight individuals (3,358.2 per 100,000).
This is a clear, modifiable risk factor – weight management can drastically cut the risk of developing NAFLD.
Smoking Increases Risk Too
Smokers had a higher incidence (8,043.2 per 100,000) than non-smokers (4,689.7 per 100,000), a 71% increase.
Smoking is not usually linked to liver fat in public perception, but this study shows it's a significant risk factor.
Rising Trend After 2010
Studies conducted after 2010 reported higher NAFLD incidence than those before, independent of location and setting.
This suggests NAFLD is becoming more common even after accounting for other factors – possibly due to lifestyle changes or better detection.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists combined 63 studies with over 1.2 million people to find out how many new cases of fatty liver disease occur each year. They found that about 46 out of 1,000 people develop it each year.
Research results
Each year, about 46 out of 1,000 people get fatty liver disease. Men get it more often than women. Overweight people get it about 3 times more than normal-weight people. Smokers get it more often.
What this means - more context
This is a high number, meaning fatty liver disease is a common and growing health problem worldwide.
To estimate the global incidence of non-alcoholic fatty liver disease (NAFLD) via systematic review and meta-analysis of cohort studies.
Meta-analysis of 63 cohort studies (1,201,807 adults) found a pooled global NAFLD incidence of 4,612.8 per 100,000 person-years. Incidence was higher in males, overweight/obese individuals, smokers, and after 2010. This study has published corrections; readers should check correction notices.
Methods Used
Systematic review and meta-analysis of cohort studies of adults without NAFLD at baseline, with ultrasound-diagnosed NAFLD. Analyzed 63 eligible studies (1,201,807 persons) from various countries. Quality assessed via Newcastle-Ottawa scale.
Main Finding
Global NAFLD incidence rate is 4,613 (95% CI 3,931.5-5,294.2) per 100,000 person-years. Males vs. females: 5,943.8 vs. 3,671.7 per 100,000. Overweight/obese vs. normal weight: ~3-fold higher incidence. Smokers vs. non-smokers: 8,043.2 vs. 4,689.7 per 100,000. Incidence increased after 2010.
Confidence Level
High for a meta-analysis with large sample and good quality studies, but limited by reliance on abstract only; full methodology details not verified. Study has corrections.
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Study has published corrections - readers should check correction notices
- •Limited to ultrasound diagnosis; may miss milder cases
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Smokers had a 71% higher NAFLD incidence than non-smokers.
Most people associate smoking with lung cancer and heart disease, not fatty liver. This finding highlights an underappreciated link.
Practical Takeaways
Maintain a healthy weight – especially if you're male or overweight – to significantly lower your risk of developing NAFLD.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 539 / 100
Probability of being correct
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
Human Meta-Analysis
Subject
Lower probability
on the GRADE evidence scale
This study looked at many other studies to figure out how many people get a liver disease called NAFLD each year. It found that some groups, like men and people who are overweight, are more likely to get it. But this doesn't prove that being male or overweight causes the disease – it just shows they are connected.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Large sample size (1,201,807 persons) increases precision.
- Systematic review methodology with explicit inclusion criteria.
- Meta-analysis provides pooled estimates and explores heterogeneity.
Weaknesses
- Full methodology not available - based on abstract only.
- Observational design cannot control for all confounders.
- Possible publication bias not assessed in abstract.
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists combined 63 studies with over 1.2 million people to find out how many new cases of fatty liver disease occur each year. They found that about 46 out of 1,000 people develop it each year.
Research results
Each year, about 46 out of 1,000 people get fatty liver disease. Men get it more often than women. Overweight people get it about 3 times more than normal-weight people. Smokers get it more often.
What this means - more context
This is a high number, meaning fatty liver disease is a common and growing health problem worldwide.
To estimate the global incidence of non-alcoholic fatty liver disease (NAFLD) via systematic review and meta-analysis of cohort studies.
Meta-analysis of 63 cohort studies (1,201,807 adults) found a pooled global NAFLD incidence of 4,612.8 per 100,000 person-years. Incidence was higher in males, overweight/obese individuals, smokers, and after 2010. This study has published corrections; readers should check correction notices.
Methods Used
Systematic review and meta-analysis of cohort studies of adults without NAFLD at baseline, with ultrasound-diagnosed NAFLD. Analyzed 63 eligible studies (1,201,807 persons) from various countries. Quality assessed via Newcastle-Ottawa scale.
Main Finding
Global NAFLD incidence rate is 4,613 (95% CI 3,931.5-5,294.2) per 100,000 person-years. Males vs. females: 5,943.8 vs. 3,671.7 per 100,000. Overweight/obese vs. normal weight: ~3-fold higher incidence. Smokers vs. non-smokers: 8,043.2 vs. 4,689.7 per 100,000. Incidence increased after 2010.
Confidence Level
High for a meta-analysis with large sample and good quality studies, but limited by reliance on abstract only; full methodology details not verified. Study has corrections.
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Study has published corrections - readers should check correction notices
- •Limited to ultrasound diagnosis; may miss milder cases
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Smokers had a 71% higher NAFLD incidence than non-smokers.
Most people associate smoking with lung cancer and heart disease, not fatty liver. This finding highlights an underappreciated link.
Practical Takeaways
Maintain a healthy weight – especially if you're male or overweight – to significantly lower your risk of developing NAFLD.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 539 / 100
Probability of being correct
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
Human Meta-Analysis
Subject
Lower probability
on the GRADE evidence scale
This study looked at many other studies to figure out how many people get a liver disease called NAFLD each year. It found that some groups, like men and people who are overweight, are more likely to get it. But this doesn't prove that being male or overweight causes the disease – it just shows they are connected.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Large sample size (1,201,807 persons) increases precision.
- Systematic review methodology with explicit inclusion criteria.
- Meta-analysis provides pooled estimates and explores heterogeneity.
Weaknesses
- Full methodology not available - based on abstract only.
- Observational design cannot control for all confounders.
- Possible publication bias not assessed in abstract.
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This study is high quality because it combined results from over a million people, which makes the numbers more trustworthy. The researchers carefully chose good studies to include. However, we only have the summary (abstract) of the study, so we can't check all the details ourselves. That means we should be a little careful about trusting everything completely.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
0 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 539 / 100
Probability of being correct
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
This design cannot establish causation — the findings describe an association, not a cause. This is a systematic review of cohort studies, which are observational. Cohort studies can show associations but cannot prove causation due to potential confounding factors.
No Conflicts
No conflicts of interest identified
No conflicts of interest identified; no funding or disclosure information provided in the text.
The text does not include any conflict of interest, funding, or author affiliation details. The study appears to be an independent meta-analysis, but without full disclosure, the absence of reported conflicts cannot be confirmed.